Pan Oscar Chi-Chien, Miller Sean, Patel Ruchin, Mukhopadhyay Shreya, Sarullo Giancarlo, Go Gwenny, Galli Jennifer, Hessels Jamie, Schlingmann-Molina Barbara, Ndashimye Emmanuel, Wen Zhiyun, Warren Christopher, Durr Eberhard, Zhang Lan, Vora Kalpit A, Fridman Arthur, Chen Zhifeng
Infectious Disease and Vaccines, Merck & Co., Inc., Rahway, NJ 07065, USA.
Analytical R&D, Merck & Co., Inc., Rahway, NJ 07065, USA.
Antibodies (Basel). 2025 Mar 27;14(2):28. doi: 10.3390/antib14020028.
There is an unmet medical need to develop a vaccine targeting endemic coronaviruses. Antigen-specific monoclonal antibodies (mAbs) are crucial for many assays to support vaccine development. In this study, we used the HuCal Fab phage display library with a diversity of 4.5 × 10 to identify antibodies specific to the spike proteins of the four endemic coronaviruses: OC43, NL63, 229E, and HKU1. As proof of concept, we established a newly designed platform using a long-read NGS workflow for antibody discovery and compared the results against the traditional workflow using Sanger sequencing consisting of lengthy and laborious benchwork. The long-read NGS workflow identified most of the antibodies seen from the Sanger sequencing workflow, and many more additional antigen-specific antibodies against the endemic coronaviruses. Overall efficiency improved up to three times, comparing the traditional workflow with the NGS workflow. Of the 113 NGS-derived mAbs isolated to bind the four endemic coronavirus spike proteins, 107/113 (94.7%) had potent ELISA binding affinities (EC50 < 150 ng/mL, or <1 nM), and 61/113 (54%) had extremely potent ELISA binding affinities (EC50 of <15 ng/mL, or <0.1 nM). We successfully developed and incorporated the long-read NGS workflow to generate target-specific antibodies with many antibodies at sub-nanomolar affinities that are likely missed by a traditional workflow. We identified strong neutralizing antibodies, proving that our endemic spike proteins are capable of generating antibodies that could offer protection against the endemic HCoVs.
开发针对地方性冠状病毒的疫苗存在未满足的医学需求。抗原特异性单克隆抗体(mAb)对于支持疫苗开发的许多检测至关重要。在本研究中,我们使用多样性为4.5×10的HuCal Fab噬菌体展示文库来鉴定针对四种地方性冠状病毒(OC43、NL63、229E和HKU1)刺突蛋白的特异性抗体。作为概念验证,我们建立了一个新设计的平台,使用长读长NGS工作流程进行抗体发现,并将结果与使用由冗长且费力的实验室操作组成的桑格测序的传统工作流程进行比较。长读长NGS工作流程鉴定出了桑格测序工作流程中发现的大多数抗体,以及更多针对地方性冠状病毒的额外抗原特异性抗体。将传统工作流程与NGS工作流程相比,整体效率提高了三倍。在分离出的用于结合四种地方性冠状病毒刺突蛋白的113种源自NGS的mAb中,107/113(94.7%)具有强大的ELISA结合亲和力(EC50<150 ng/mL,或<1 nM),61/113(54%)具有极强的ELISA结合亲和力(EC50<15 ng/mL,或<0.1 nM)。我们成功开发并纳入了长读长NGS工作流程,以产生具有许多亚纳摩尔亲和力抗体的靶标特异性抗体,而这些抗体很可能会被传统工作流程遗漏。我们鉴定出了强效中和抗体,证明我们的地方性刺突蛋白能够产生可提供针对地方性人冠状病毒保护作用的抗体。